Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transcode Therapeutics Inc (RNAZ)

Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,868
  • Shares Outstanding, K 917
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,750 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.40 +2.50%
on 03/24/26
10.40 -17.21%
on 03/04/26
-1.00 (-10.41%)
since 02/27/26
3-Month
6.08 +41.54%
on 12/29/25
12.60 -31.67%
on 01/26/26
+1.65 (+23.71%)
since 12/26/25
52-Week
6.08 +41.54%
on 12/29/25
22.03 -60.91%
on 05/01/25
-5.11 (-37.24%)
since 03/28/25

Most Recent Stories

More News
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

BOSTON , March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) , a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer,...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

BOSTON , Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

BOSTON , Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

BOSTON , Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

BOSTON , Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer,...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

BOSTON , Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Completes Phase 1a Trial for TTX-MC138

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

BOSTON , Oct. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or...

RNAZ : 8.61 (+0.35%)
TransCode Therapeutics Acquires Polynoma and Secures Investment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.61 (+0.35%)

Business Summary

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 9.13
2nd Resistance Point 8.96
1st Resistance Point 8.79
Last Price 8.61
1st Support Level 8.45
2nd Support Level 8.28
3rd Support Level 8.11

See More

52-Week High 22.03
Fibonacci 61.8% 15.94
Fibonacci 50% 14.06
Fibonacci 38.2% 12.17
Last Price 8.61
52-Week Low 6.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.